Trial Profile
Evaluation of the Efficacy of Vortioxetine for Posttraumatic Stress Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2021
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- 13 Feb 2021 Primary endpoint, Change in PTSD scale score, has not been met as per results published in the Journal of Clinical Psychopharmacology
- 13 Feb 2021 Results published in the Journal of Clinical Psychopharmacology
- 21 May 2020 Status changed from recruiting to completed.